Trials / Completed
CompletedNCT00374179
CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-322 | IV solution, weekly or bi-weekly |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2008-11-01
- Completion
- 2009-02-01
- First posted
- 2006-09-11
- Last updated
- 2009-02-24
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00374179. Inclusion in this directory is not an endorsement.